The abstract is read at the publisher; the summary is JClub's.
Neoadjuvant cemiplimab in resectable stage II to IV cutaneous squamous cell carcinoma shows durable 54-month event-free survival of 76.2%, with no late recurrences.
- Why it matters: The study addresses uncertainty about long-term durability and late relapse risk after neoadjuvant immunotherapy in resectable stage II to IV CSCC.
- What they did: In a multicenter phase II trial (NCT04154943), final EFS and overall survival were assessed at a median 54-month follow-up, tracking 16 EFS events and overall survival outcomes.
- The result: At final analysis, there were no new disease recurrence events; 54-month EFS was 81.5% with pCR and 100% with partial pathologic response, while 54-month OS was 79.4% with no new grade ≥3 safety signals.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.